Novartis has announced successful results from two Phase 3 trials of its antibody drug ianalumab in Sjögren’s syndrome, marking the first global studies demonstrating statistically significant improvement in disease activity for this chronic autoimmune disorder. The trials, involving 779 patients, showed favorable safety and efficacy profiles, positioning ianalumab as a leading candidate for regulatory approval. This development follows Novartis's recent discontinuation of another Sjögren’s asset and represents a major advance in a field where therapeutic options remain limited. The company plans to engage with health authorities to pursue approval of the drug, which targets BAFF-R to modulate B-cell activity.